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97% cystine. At that time, his serum creatinine was 1.6 mg/dL;
creatinine clearance, 90 mL/min; and protein excretion, 100
mg/24 h.
The patient moved to St. Louis 4 years ago and was stable
until he presented with right flank pain 3 years ago. His medica-
tions at the time of his visit to the stone center included mesala-
mine and loperamide. His family history was notable only for
a brother with cystinuria. He did not drink alcohol except so-
cially on occasion; he smoked one pack of cigarettes/day for
20 years. He did not use illicit drugs.
The physical examination was normal except for multiple sur-
gical scars and an ileostomy appliance containing liquid feces.
Laboratory tests were ordered, and the patient entered Barnes
Hospital for ureteroscopic laser lithotripsy of a right mid-ure-
teral stone before he could begin therapy. He was discharged to
the renal stone center, where laboratory data revealed a serum
creatinine of 1.6 mg/dL; creatinine clearance of 93 mL/min;CASE PRESENTATION
urinary cystine excretion, 620 mg; and 1 to 2 white blood cells/
A 41-year-old white man was referred to the Washington high-power field on urinalysis. Treatment was begun with N-(2-
University renal stone center 3 years ago following a uretero- mercaptoproprionyl) glycine (tiopronin), 100 mg qid, and po-
scopic lithotripsy for an obstructing right mid-ureteral stone 2 tassium citrate, 10 mEq bid.
months earlier. The patient was asymptomatic and had an un- Four months later, the patient was seen in follow-up at the
remarkable dietary history. stone center. The physical examination revealed a blood pres-
His medical history was long and complicated. He had had sure of 135/90 mm Hg; serum creatinine, 1.7 mg/dL; creatinine
recurrent nephrolithiasis since his childhood, and he carried clearance, 80 mL/min; urine volume, 2.7 L/day; and cystine
the diagnosis of cystinuria. He had undergone a left nephrec- excretion, 400 mg/day. A small mixed disulfide peak (cysteine-
tomy 24 years ago at age 17 for complications during a nephro- tiopronin) was apparent in the amino acid analysis. Urinalysis
lithotomy for a staghorn calculus. He had stopped forming revealed 5 to 7 white blood cells/high-power field.
renal stones until 11 years ago, when he developed an ileocolic One month later, he presented to the Barnes Hospital emer-
fistula and was diagnosed with Crohn’s disease. After several gency department because of anuria of two days duration and
intestinal resections and development of various fistula tracks, low back pain on the right side. Sonography revealed ureteral
he underwent an ileostomy 6 years ago. Following recovery, obstruction and a 1 cm stone at the pelvic brim just above the
his inflammatory bowel disease was controlled by medications. bladder. The patient underwent cystoureteroscopic extraction
He gained weight and developed a stable ileostomy excretory of the stone.
volume of approximately 1.5 L/day. However, he experienced At the stone center one month later, evaluation revealed:
recurrent nephrolithiasis. Four years ago, he was treated for blood pressure, 140/95 mm Hg; serum creatinine, 2.1 mg/dL; cre-
renal colic in the Department of Urology at the University of atinine clearance, 40 mL/min; protein excretion, 500 mg/day;
Alabama. He had a 2.5 cm stone in the renal pelvis, which re- and urine volume, 1.9 L/day. Urinalysis demonstrated 15 to
quired percutaneous nephrolithotomy; the extracted stone was 20 white blood cells/high-power field. Enalapril was added to
his therapeutic regimen, 10 mg/day, and the tiopronin was in-
creased to 200 mg qid.The Nephrology Forum is funded in part by grants from Amgen, In-
The patient still did not achieve remission of his nephrolithia-corporated; Merck & Co., Incorporated; Dialysis Clinic, Incorporated;
sis. An episode of right flank pain 2 years ago prompted anotherand Bristol-Myers Squibb Company.
sonogram, which demonstrated a ureteropelvic junction stone.
Key words: obstructive uropathy, ureteral obstruction, tubulointersti- Extracorporeal shockwave lithotripsy was performed. His se-
tial nephritis, BMP-7, OP-1. rum creatinine after the procedure and ureteral stent removal
was 1.8 mg/dL. 2002 by the International Society of Nephrology
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At the renal stone center 4 months later, his blood pressure tors for the crystals of cystine are not known, as they
was 130/80 mm Hg. Urinalysis revealed 5 to 7 white blood cells/ are for calcium oxalate. Most likely, recurrent ureteral
high-power field. Sonography disclosed no stones. The right kid- obstruction is the cause of interstitial nephritis in cystinu-
ney measured 11.8 cm. The tiopronin was increased to 1200 ria [1].mg/day; enalapril and potassium citrate therapy were continued
This is not the first Nephrology Forum dedicated tounchanged. Six months later, his blood pressure was 130/80
chronic tubulointerstitial disease and ureteral obstruc-mm Hg; urinalysis revealed 2 to 4 white blood cells/high-power
tion. The topic was discussed by Saulo Klahr in 1998 onfield and no crystals. The serum creatinine was 1.6 mg/dL; cre-
atinine clearance, 96 mL/min; and urine volume, 2.7 L. Sonog- the occasion of the twentieth anniversary of the Nephrol-
raphy revealed no stones and a right kidney measuring 12.1 cm. ogy Forum [3]. That Forum presented an excellent re-
The patient was last examined three months ago. His blood view of the pathophysiology of renal fibrosis stimulated
pressure was 130/80 mm Hg; urinalysis revealed 0 to 2 white by obstructive uropathy, and I will not repeat the points
blood cells/high-power field, and sonography revealed no
he made. I refer the reader to Dr. Klahr’s Forum. Ob-stones. The serum creatinine was 1.5 mg/dL; creatinine clear-
structive uropathy can manifest as a sudden decrease inance, 95 mL/min; urine protein excretion, 275 mg/day; cystine
renal function. But gradual and insidious decreases inexcretion, 250 mg/day; there was a large mixed disulfide peak
renal function similar to those seen in today’s patientin the amino acid profile. Liver function tests were normal.
Therapy with tiopronin, 1200 mg/day; enalapril, 10 mg/day; are also observed. The decrease in renal function can be
potassium citrate, 10 mEq tid; mesalamine; and loperamide halted or even reversed if obstruction is relieved and
was continued. prevented, and if the tubulointerstitial inflammation re-
solves spontaneously or with treatment. Thus, obstructive
uropathy is a potentially treatable form of chronic tubulo-DISCUSSION
interstitial nephritis. Today’s case presentation highlights
Dr. Keith A. Hruska (Professor of Pediatrics, Medi-
the treatable nature of tubulointerstitial nephritis, and
cine, Cell Biology and Biophysics, and Chief, Division of
it directs attention to our current therapeutic arsenal,
Pediatric Nephrology, Washington University, St. Louis, which is limited to relief of obstruction and inhibition of
Missouri, USA): The patient for discussion today almost angiotensin II either by angiotensin-converting enzyme
certainly had active chronic tubulointerstitial nephritis (ACE) inhibition or angiotensin II receptor (AT1 and
for at least two years due to repeated bouts of obstructive AT2) blockade. A new therapeutic agent and its poten-
uropathy, cystinuria, and nephrolithiasis involving a sin- tial to mitigate the pathophysiology of tubulointerstitial
gle kidney. He was successfully treated with angiotensin- nephritis will be the focus of my discussion today.
converting-enzyme inhibition and conversion of cystine
to a mixed disulfide of cysteine-mercaptopropionylgly- Pathophysiology of obstructive uropathy
cine. These agents restored the glomerular filtration rate Obstructive uropathy can be due to anatomic or func-
(GFR) to baseline, decreased his proteinuria, and allevi- tional abnormalities of the renal pelvis, ureters, bladder,
ated his pyuria. or urethra. The result of the obstruction, however pro-
Today’s patient is atypical in that recurrent nephroli- duced, is hydrostatic-pressure-induced injury to the tu-
thiasis is not a common cause of tubulointerstitial nephri- bular epithelium, especially that of the collecting duct
tis. However, this patient was at risk because of his single (Fig. 1). As a result of injury, the epithelium loses fea-
kidney and the recurrent episodes of obstructive uropa- tures of the differentiated phenotype. Epithelial cells can
thy and instrumentation. Pyuria and a reduction in creati- move into the cell cycle and apoptose or produce dedif-
nine clearance, which developed insidiously between epi- ferentiated daughter cells that express increased produc-
sodes of urinary tract obstruction due to ureteral stones, tion of extracellular matrix. They can even undergo epi-
heralded the onset of tubulointerstitial nephritis. At its thelial-mesenchymal transdifferentiation, migrate from the
peak, the serum creatinine was twice the baseline level, and epithelium, and contribute to the pool of interstitial myo-
the creatinine clearance was reduced by 50%. The devel- fibroblasts. The tubular injury leads to tubulointerstitial
opment of hypertension, heavy pyuria without hema- inflammation, tubular atrophy, and fibrosis, eventually
turia, and protein excretion of less than 1 g/24 h is producing end-stage renal failure unless the process is
indicative of the presence of tubulointerstitial nephritis. reversed [4].
This patient also was at risk for interstitial inflammation Interstitial fibrosis is a common consequence of long-
from calcium oxalate crystalluria, which often compli- standing obstructive uropathy. Fibrosis likely develops
cates Crohn’s disease and can cause tubulointerstitial due to an imbalance between extracellular matrix synthe-
inflammation [1]. However, at no time was there evi- sis and deposition, and matrix degradation. The mecha-
dence of calcium oxalate crystalluria. Cystinuria as a cause nisms underlying fibrogenesis of obstructive uropathy
of tubulointerstitial inflammation is less clear than calcium have been extensively investigated [4–7]. Nearly 3 de-
oxalate crystalluria because the defect in cystinuria is de- cades ago, Nagel and Bulger reported widening of the
interstitial space following 7 days of ureteral obstructioncreased cystine transport [2], and specific epithelial recep-
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mation of renal cells to interstitial myofibroblasts and
diminish infiltration of the interstitial compartment by
inflammatory cells [19, 20]. However, limiting angioten-
sin II production even through direct modulation of an-
giotensinogen expression does not attenuate tubular atro-
phy [16]. We recently demonstrated that a new potential
therapy for chronic renal disease, bone morphogenic pro-
tein (BMP-7), was more effective than ACE inhibition in
preserving renal structure and function in rats with UUO
[21]. I will return to a discussion of BMP-7 later.
Before that, I would like to focus on leukocyte infiltra-
tion of the renal interstitium. The few resident macro-
phages in the cortex of normal kidneys are mainly in
glomeruli [22]. The normal medulla is completely devoidFig. 1. Effects of obstruction-induced injury on the collecting duct epi-
thelium. The epithelium undergoes rapid changes involving loss of many of leukocytes. In obstructive uropathy, mononuclear cells
features of its terminally differentiated phenotype. The apical microvilli are present in both the renal cortex and medulla [23]. A
become effaced; cell height is reduced; the tight junctions lose many
cellular-rich infiltrate composed mainly of macrophagesof their properties and functions; ion transport is reduced and can
become non-vectorial. Extracellular matrix production is increased pos- was detected as early as 4 hours after the onset of ureteral
sibly because of transdifferentiation to interstitial myofibroblasts. obstruction in rats, but the peak response occurred after
24 hours [23]. The second most abundant cells of the in-
terstitial infiltrates were T-lymphocytes of the cytotoxic
suppressor cell subclass [23]. T-lymphocytes of the helperin rabbits, with an increase in collagen fibers and fibro-
type did not account for a significant portion of the in-blasts. By day 16 of obstruction, collagen was greatly in-
filtrate, despite their predominance in the peripheralcreased and arranged in large bundles. Nagel and Bulger
circulation. Ureteral obstruction for less than 24 hoursalso described a mononuclear cell infiltrate and prolifera-
produced only a scant infiltration of B lymphocytes ortion of interstitial cells in the renal parenchyma following
neutrophils in the kidney [23]. The mononuclear cellchronic unilateral ureteral obstruction [6]. Interstitial fi-
infiltrate disappears slowly following release of obstruc-brosis and thickening of the tubular basement membrane
tion in animals, returning to basal levels only after severalfollowing unilateral obstruction are associated with in-
days. The macrophage content of the cortical interstitium
creased deposition of several extracellular matrix mole-
increases moderately in the first two days after release of
cules, including collagen types I, III, IV, XV, and XVIII, obstruction and then decreases over the next four days
fibronectin, and heparan sulfate proteoglycans [7, 8]. to pre-obstruction levels. T-lymphocytes in the cortex
Animal models have illuminated our understanding of were diminished to less than 20% of their value during
the complex milieu of renal diseases associated with in- obstruction within two days of release of ureteral ob-
terstitial fibrosis. Moller et al utilized the model of uni- struction [23].
lateral ureteral obstruction (UUO) to study the patho- The signals responsible for recruiting macrophages
physiology of tubulointerstitial disease [9]. Unilateral and suppressor T-cells into the renal interstitium of rats
ureteral obstruction in the rat and mouse produce tubu- following unilateral ureteral obstruction appear to be spe-
lointerstitial inflammation and fibrosis that seem to mir- cific for these cells, as neutrophils were not detected in
ror the human condition produced by obstructive uropa- the compartment. The factors involved in cellular infil-
thy. In this model, hypertension, proteinuria, and lipid tration of the interstitium of the obstructed kidney have
dysregulation do not contribute to progressive nephron been partially characterized. Supernatants prepared from
destruction [3, 10–13], and glomerular injury is not prom- renal cortices of rats with UUO had greater chemotactic
inent early in the course of the injury produced. Uremia activity for peritoneal macrophages than did superna-
is avoided by the function of the contralateral kidney, tants from the contralateral kidney of the same rats [24].
which undergoes hypertrophy and hyperplasia as the This macrophage chemotactic activity peaked between
obstructed kidney is destroyed. The renal injury of UUO 4 and 12 hours of obstruction and declined after longer
is mediated in part through stimulation of renal angioten- periods, 24 to 72 hours. Among the molecules responsi-
sin II production, which activates TGF- in a cascade ble for this chemotactic activity, monocyte chemoattrac-
of events culminating in tubulointerstitial inflammation tant peptide-1 (MCP-1), which is expressed in tubular
and fibrosis [14–18]. Inhibition of angiotensin II produc- epithelium at 12 hours following ureteral obstruction
tion by ACE inhibitors decreases the expansion of the and persists as long as 96 hours, is a key participant
renal interstitium associated with fibrosis [19, 20]. We [15]. Other members of the chemokine family such as
RANTES and interleukin-8 (IL-8) also play a role.have shown that ACE inhibitors also decrease transfor-
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Table 1. Factors exhibiting increased expression in kidneysOsteopontin, a multifunctional protein with potent che-
with ureteral obstruction
motactic activity, is upregulated by ureteral obstruction,
and macrophage infiltration following UUO in the osteo- Vasoactive compounds
Angiotensinogen, angiotensin II, endothelin, thromboxane A2pontin knockout mouse is diminished [8]. Other substances
Growth factors
such as transforming growth factor beta (TGF-), intra- Transforming growth factor- (TGF-1), basic fibroblast growth
factor (bFGF)cellular adhesion molecule-1 (ICAM-1), and vascular
Cytokinescell adhesion molecule-1 (VCAM-1), which are overex-
Tumor necrosis factor- (TNF-), interleukin-6 (IL-6), platelet
pressed following ureteral obstruction, also play roles in activating factor (PAF)
Chemoattractants/chemokinesmacrophage recruitment [25, 26].
Monocyte chemoattractant peptide-1 (MCP-1), osteopontinThe volume of the renal cortical interstitium increases
Immediate early response genes
rapidly following UUO in the rat kidney [19, 21, 27]. By c-fos, c-jun, jun B, c-myc, cH-Ras
Cell cycle proteinsthree days following unilateral obstruction, interstitial
Protein 53 (p53), protein 21 (p21, WAF-1)volume was increased from 10% of the cortex to 29%
Proteins associated with apoptosis
(abstract; Duan et al, J Am Soc Nephrol 7:1697, 1996) and Clusterin (SGP-2), osteopontin
Transcription factorsto 47% by five days following obstruction [21]. Deposi-
Nuclear factor-B (NF-B)tion of collagen types I, III, and IV was increased in the
Extracellular matrix proteins
tubulointerstitium by the third day of obstruction. In ad- Collagen types I, III, IV, XV, and XVIII, tissue inhibitor of
metalloproteinases-1 (TIMP-1), decorin, fibronectin, alternatedition, the level of mRNA for collagen 1 (IV) was sig-
splice formsnificantly greater in the obstructed kidney at that time.
Adhesion proteins
Thus, events leading to interstitial fibrosis occur promptly Intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion
molecule-1 (VCAM-1)following the onset of obstruction. By contrast, the
amounts of collagen I, III, and IV did not change in the
glomeruli of the obstructed kidney, even after five days
of unilateral obstruction. These results were consistent
important source of the myofibroblast phenotype and awith the finding that glomeruli appear normal by light
component of the tubular pathology produced by ure-microscopy after seven days of obstructive nephropathy.
teral obstruction.Renal tubular cells contribute to the increased produc-
What pathways lead to interstitial fibrosis in obstruc-tion and deposition of type IV collagen in tubular base-
tive uropathy? A number of cytokines, vasoactive com-ment membranes and interstitium following obstruction.
pounds, chemoattractant molecules, and growth factorsRenal tubular cells in culture produce collagen types I,
are upregulated after the onset of obstructive uropathyIII, and IV. The expression of collagen 1 (IV) mRNA
(Table 1). Several studies [20, 29, 31, 32] suggest that theis substantially increased in the tubules of the obstructed
renin-angiotensin system is activated after ureteral ob-kidney. Nagel and Bulger reported that fibroblasts mi-
struction. Increasing levels of angiotensin II stimulate thegrated to, and proliferated in, the interstitium of the
expression of other factors, such as TGF-1 and TNF-,obstructed kidney during UUO [6]. In addition, Kuncio
which instigate a damage program in the renal intersti-and colleagues found that several cytokines secreted by
tium (Table 1). These instigating molecules representinfiltrating macrophages and T-lymphocytes stimulate
the early steps in a signal transduction pathway that cul-fibroblast proliferation, and that interstitial fibroblasts
minates in interstitial fibrosis.produce collagen types I, III, and IV [28]. The substantial
A multifunctional cytokine and growth factor, trans-increase in collagen types I and III found in the intersti-
forming growth factor- (TGF-), participates widely intium of the obstructed kidney at days 3, 4, or 5 following
embryonic development and in regulating repair and re-UUO is consistent with the increased cellularity due
generation following tissue injury [33, 34]. Transformingto fibroblast proliferation and infiltrating mononuclear
growth factor- also is involved in angiogenesis, regula-cells. Thus, interstitial fibroblasts probably contribute to
tion of inflammation, integrin expression, protease activ-the increase in collagen production in the obstructed
ity, and apoptosis [35]. Of the three main TGF- iso-kidney of rats. Our group [29] and others [30] have re-
forms, TGF-1, TGF-2, and TGF-3, TGF-1 is mostported that -smooth muscle actin mRNA and protein
important in interstitial nephritis. Synthesized as a 391and the intermediate filament desmin are upregulated
amino acid procytokine, TGF-1 comprises a C-terminalin the obstructed kidney of rats following UUO. The
TGF- sequence and a larger N-terminal region that,overexpression of -smooth muscle actin and desmin
after processing, forms a protein called latency-associ-indicates the myofibroblast phenotype. The origin of the
ated peptide (LAP). As TGF- is secreted in an inactivemyofibroblast is likely bimodal following ureteral ob-
(latent) form because of its association with the LAP,struction. A significant source of the myofibroblast de-
binding to receptors is prevented. The LAP-TGF-1 com-rives from transformation of interstitial fibroblasts. How-
ever, epithelial-mesenchymal transdifferentiation is an plex (the small latent complex) is stored at the cell surface
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in the extracellular matrix, and it is associated with an- function of BMP-7 in the kidney and its role in renal
injury are unknown, this protein might have a cytopro-other LAP, which in most cases is the latent TGF-
binding protein-1 (LTBP1). This protein has sequence tective effect, or it might regulate chemotactic cytokines
involved in monocyte infiltration associated with a vari-similarity to the fibrillins. The complex of all three pro-
teins is called the large latent complex, and through ety of renal diseases. In addition to its role as a renal
morphogen, BMP-7 probably is a critical renal tubularLTBP1 it can be linked to the extracellular matrix. In the
case of the renal interstitium, perhaps the proteoglycan differentiation factor determining epithelial cell pheno-
type. Therefore, we analyzed a potential role of BMP-7decorin serves as the link [15, 36].
The LAP–TGF- complex in the extracellular matrix in preventing tubulointerstitial fibrosis.
To assess the effect of BMP-7 on preservation of renalcan be activated by binding of the small LAP to throm-
bospondin or to cell surface integrins. Latency-associ- function following injury, we performed renal clearance
studies in each of the kidneys of rats after 5 days ofated peptide-1 contains an arginine-glycine-aspartic
acid (RGD) sequence, which is a binding site motif for UUO and 5 days of recovery. We used enalapril-treated
animals (25 mg/kg) as a positive control for comparisona subset of integrins. Binding changes the confirmation
of the LAP protein, releasing the mature TGF- mole- purposes. As Figure 2A illustrates, renal function did
not recover in the post-obstructed kidneys of vehicle-cule for binding with cell surface receptors [37] or with
thrombospondin in an active state. Biologically active or enalapril-treated animals. However, 50% of the post-
obstructed kidneys in the 100 g/kg and 300 g/kg BMP-7TGF-1 is a 25 kD dimer composed of two processed ma-
ture proteins linked by a disulfide bond. Active TGF-1 treated groups had return of urine flow following release
of UUO. The mean glomerular filtration rate (GFR) inis a critical factor involved in tubulointerstitial fibrosis
(Table 1). It increases matrix protein synthesis, inhibits the post-obstructed kidneys of animals in the 100 and
300g/kg BMP-7 groups was 0.19 and 0.21 mL/min/100 gmatrix protein degradation, and upregulates integrin ma-
trix adhesion factors. Transforming growth factor- stim- bw, or 34% and 38% of normal GFR values, respectively.
The GFR of the contralateral kidneys tended to be in-ulates production of a wide variety of proteins found
in the extracellular matrix during obstructive uropathy creased in both the enalapril-treated group and vehicle
group when compared to sham animals; this finding sug-including fibronectin, collagen types I, III, IV, thrombo-
spondin, osteonectin, tenascin, elastin, hyaluronic acid, gested compensatory hypertrophy. Contralateral renal
hypertrophy was less in the BMP-7–treated groups. Re-SPARC, and proteoglycans such as biglycan and decorin
(Table 1). Transforming growth factor-1 inhibits matrix nal blood flow was assessed by para-amminohippurate
(PAH) clearances; as a result, assessment of effectivedegradation by increasing the activity of tissue inhibitors
of metalloproteinases (TIMPS) and decreasing the activ- renal blood flow was limited to the animals with return
of urine flow. Mean single-kidney PAH clearances wereity of metalloproteinases (MMPs). It also stimulates the
synthesis of receptors for extracellular matrix proteins. 1.0 and 1.2 mL/min/100 g bw in the 100 and 300 g/kg
bw BMP-7 groups, respectively, or 58% and 68% of theFurthermore, TGF-1 is a chemoattractant for fibro-
blasts [38] and stimulates fibroblast proliferation. values obtained in sham-operated normal rats. Renal
blood flow in the contralateral kidneys was not altered,
Bone morphogenic protein-7 with the exception of a modest but significant (P 0.05)
increase in the enalapril-treated group; this increase indi-Bone morphogenetic protein-7 (BMP-7), also known as
osteogenic protein-1 (OP-1), is a member of the TGF- cated contralateral renal hypertrophy.
To improve the comparison of renal function protec-superfamily and a key morphogenic signal for renal de-
velopment [39]. The protein continues to be produced tion among the various groups, in a subsequent study we
decreased the severity of the renal injury to three daysin adult mammals [40–43], predominantly within the kid-
ney [44, 45], but also is found in the circulation (Sampath of UUO and seven days of recovery. Either BMP-7 or
enalapril was given intraperitoneally beginning at theTK, unpublished observations). Deletion of BMP-7 in
mice results in failure of differentiation of the metaneph- time of ureteral obstruction, and the investigators treat-
ing the animals as well as those performing the clearanceric mesenchyme and leads to loss of mesenchymal cell
condensation around the ureteric bud and eventually to studies were blinded to the treatment group; hence, a
double-blind, placebo-controlled format was used. Fig-glomerular and tubular agenesis and severely hypoplas-
tic kidneys [39, 40, 46]. Animals deficient in BMP-7 die ure 2B shows that urine flow was re-established in the
vehicle-treated (placebo) group (N  8), and the GFRshortly after birth because of uremia. Many features of
development are recapitulated during repair of renal was 0.16 mL/min/100 g bw, compared to 0.33 in the sham-
operated normal animals. Thus the experimental windowinjury, and BMP-7 might be important both in preserva-
tion of function and resistance to injury [47]. Bone mor- was narrowed in this study. The GFR in the enalapril
group (N 8) was 0.21 mL/min/100 g bw, not statisticallyphogenic protein-7 decreases the loss of renal function
associated with acute ischemic injury [47]. Although the better than that in the vehicle group. The GFR of the
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produce an additional benefit, probably because of the
maximal doses of both agents used.
To further test the therapeutic potential of BMP-7, we
changed the protocol from a prevention to a treatment
strategy by delaying institution of the test agents until
release of the obstruction at day 3. In this treatment trial
(Fig. 2C), the GFR of the post-obstructed kidneys of
animals in the BMP-7 treated group, 0.22 mL/min/100 g
bw, was significantly higher than that in post-obstructed
kidneys of the vehicle-treated group, and also greater
(P  0.06) than that in the post-obstructed kidneys of
animals treated with enalapril. Thus, in three separate
trials including a treatment trial, BMP-7 significantly pro-
tected renal function and was more potent than a maxi-
mal dose of an ACE inhibitor.
Treatment with BMP-7 prevented the infiltration of
the renal parenchyma by macrophages following UUO.
Using a monoclonal antibody (ED-1) to a macrophage-
specific antigen, Diamond et al quantitated the cellular
infiltration of the interstitium following UUO [15]. Using
this techinque, we demonstrated that administration of
BMP-7 at 100 or 300 g/kg bw reduced the macrophage
infiltration by 55% and 72%, respectively, in the UUO
kidneys from rats in which obstruction was released at
day 5 prior to analysis at day 10. Although enalapril
also was effective, the protective effect of 300 g/kg bw
BMP-7 every other day was significantly greater.
We analyzed the degree of tubulointerstitial fibrosis
in cortical sections of rat kidneys subjected to either
5 or 10 days of UUO. Masson trichrome-stained sections
were used to analyze the accumulation of collagen in the
interstitium. As Figure 3 shows, collagen was apparent in
the Bowman’s capsule of normal kidneys, the perivascu-
lar adventitia (Fig. 3A), and in the renal capsule (Fig. 3B).
In comparison, kidneys subjected to UUO for five days,
with release and recovery for five days prior to analysis
at day 10, had massive accumulation of collagen in the
expanded interstitium along with cellular interstitial in-
filtrates (Figs. 3C and 3D). Contralateral, non-ligated
Fig. 2. Recovery of renal function following release of unilateral ure- kidneys in all the experimental groups were indistin-
teral obstruction in three protocols. A. Inulin clearances following 5
guishable from normal kidneys. Kidneys from rats givendays of obstruction and 5 days of recovery in obstructed ( ) and contra-
lateral () kidneys. BMP-7 and enalapril were begun at the time of 100 g/kg bw of BMP-7 with five days of UUO prior to
UUO (prevention protocol). B. Inulin clearances following 3 days of release of the obstruction and examination at day 10 had
obstruction and 7 days of recovery in obstructed (), control ( ), and
minimal interstitial collagen deposition (Figs. 3E and 3F).sham-operated ( ) kidneys. BMP-7 and enalapril were begun at the
time of UUO. C. Inulin clearances following 3 days of obstruction and Rats treated with 300 g/kg bw of BMP-7 had almost
7 days of recovery in obstructed (), contralateral ( ), and sham- no renal interstitial collagen deposition following UUO
operated kidneys. BMP-7 and enalapril were begun at the time of
(Figs. 3G and 3H). Expansion of the interstitial spacerelease of the UUO (treatment protocol). In each protocol, BMP-7,
100g/kg bw, was significantly more effective than enalapril in restoring after UUO is apparent in Figure 3 (C and D), and this
GFR toward normal. was quantitated. Unilateral ureteral obstruction with re-
lease at five days and analysis at 10 days revealed a
fivefold expansion of the interstitial space, from 9.7% totwo groups given doses of BMP-7 did not differ, and the
47.4% of the cortical volume (P  0.001). In the groupgroups were combined for analysis. The GFR was 0.28
of rats given 300 g/kg bw of BMP-7, the expansion ofmL/min/100 g bw (P  0.02) in the BMP-7–treated ani-
the interstitial space was only 17.1% (less than twofoldmals, significantly higher than that in the vehicle-treated
animals. Combination of BMP-7 and enalapril did not above normal). Administration of 300 g/kg bw of BMP-7
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Fig. 3. BMP-7 prevents renal fibrogenesis
following UUO. Coronal sections of kidneys
stained with the Masson trichrome stain for
collagen. With this stain, collagen fibrils stain
blue, whereas the cells stain red. A, B are sec-
tions from the cortices of both kidneys of
sham-operated animals. Collagen is detected
in the renal capsule around larger vessels and
Bowman’s capsule. Little collagen is detect-
able in the renal interstitium. C, D are sections
from two different areas of the obstructed kid-
ney of a vehicle-treated animal. There is wide-
spread and diffuse blue stain of the interstitial
collagen, and a major interstitial cellular infil-
trate. E, F are two sections of the cortex of
an obstructed kidney from an animal treated
with 100 g/day bw of BMP-7. The amount
of interstitial collagen is only slightly more
than that in the sham-operated kidneys. G, H
are two sections from the cortex of a kidney
from an animal treated with 300 g/day bw
of BMP-7. The amount of interstitial collagen
is indistinguishable from the interstitial colla-
gen deposition in the sham-operated animals.
[Reprinted with permission of the American
Physiology Society from Am J Physiol (Renal
Physiol) 280:F130-F143, 2000.]
was significantly more effective than the administration abut basement membranes of neighboring tubules in
normal and contralateral kidneys. In obstructed kidneys,of 100 g/kg bw of BMP-7 (P  0.03). Treatment with
BMP-7 at either dose afforded greater protection than expansion of the interstitial compartment increases the
distance between tubular basement membranes. Typedid enalapril (P  0.01), which our group has previously
shown to be renoprotective in this model of fibrogenesis IV collagen staining of the tubular basement membrane
was decreased in UUO, and type IV collagen was aber-[19, 20].
We further examined the expansion of the renal inter- rantly expressed as a component of the interstitial colla-
gen accumulation. The interstitial myofibroblast respon-stitium following UUO by analyzing the deposition of
type IV collagen. Type IV collagen is a normal compo- sible for deposition of the increased interstitial collagen
matrix in tubulointerstitial fibrosis secretes type IVnent of tubular basement membranes, which frequently
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collagen [48]. Thus, type IV collagen staining serves the mechanism of renal protection with BMP-7 treat-
ment and that with enalapril treatment. The informationboth as a measure of interstitial volume and as a marker
suggests that the mechanism of BMP-7–induced renalof interstitial collagen accumulation. Treatment with
protection is related to preservation of renal tubularBMP-7 diminished the distance between tubular base-
epithelial integrity, and that this mechanism might havement membranes, thus confirming the interstitial volu-
suppressed the tubulointerstitial inflammation and fi-metric measurements shown in Figure 3, and decreased
brosis due to the UUO-stimulated, angiotensin II-medi-the deposition of type IV collagen in the interstitium.
ated damage cascade.We next examined the expression of alpha smooth mus-
We further investigated the mechanism of renal tubu-cle actin (-SMA), a marker of the tubulointerstitial myo-
lar epithelial preservation following UUO by examiningfibroblast responsible for a large component of intersti-
whether apoptotic loss of epithelial cells, which contrib-tial collagen deposition following UUO. In the normal
utes to tubular atrophy and is increased by UUO [50],and contralateral kidneys, -SMA was expressed only in
was affected by BMP-7 treatment. We examined sectionsthe blood vessels, but it was prominently expressed in the
of kidney, similar to those in Figure 4, using the TUNELinterstitium of the kidneys subjected to 5 days of UUO
assay for apoptotic nuclei. In vehicle-treated rats thatand released prior to analysis at day 10. Administration
had undergone 5 days of UUO with analysis on day 10,of BMP-7 significantly reduced interstitial -SMA, as dem-
a significant increase (P  0.001) in apoptotic nuclei ofonstrated by a lesser histologic immunostaining score of
epithelial cells was found, from an average of 1.7 per-SMA. The effect of BMP-7 on-SMA histologic scores
200 microscopic field in the kidney of sham-operatedwas dose dependent, and the 300 g/kg bw dose was sig-
animals to 30.1 apoptotic nuclei per 200 field. Bothnificantly more effective than enalapril in preventing ac-
doses of BMP-7 significantly reduced the number of apo-cumulation of cells expressing -SMA in the interstitium.
ptotic nuclei by about one-third (P  0.001). EnalaprilWe also analyzed the protective action of BMP-7 dur-
produced a modest but significant decrease (0.05) ofing a longer period of UUO sufficient to produce a severe
about 10% in tubular epithelial cell apoptosis.injury that would be irreversible in the experience of
Tubular epithelial morphology in the medulla was pre-most investigators. Ten days of sustained UUO in vehi-
served by BMP-7 treatment. After UUO for 5 days withcle-treated rats further increased interstitial volume from
recovery for 5 days following release, the medullary col-47.4% in the 5-day obstruction/5-day release group to
lecting duct was characterized by flattened, effaced epi-57.2%. This increase, while significant, represents some
thelia. The BMP-7 dose dependently preserved epithelialleveling off in the rate of interstitial volume increase.
morphology. Associated with preservation of epithelialConcordant with this observation, we noted no further
cell morphology, expression of BMP-7 was protected.induction of -SMA or increase in the interstitial type
The BMP-7 was expressed in the normal collecting ductIV collagen score when comparing values from the re-
epithelia [44, 45] and its expression was preserved bylease at 5 days to the 10-day sustained UUO animals.
BMP-7 treatment but not by enalapril. Because the half-Treatment with BMP-7, especially using the 300 g/kg
life of BMP-7 is short, and the last dose in our studiesbw dose, significantly decreased interstitial volume, col-
was administered 48 hours prior to analysis, exogenouslagen IV matrix score, and expression of -SMA. Visual
BMP-7 was not detected by immunostaining.inspection of the immunocytochemistry for collagen IV
In summary, BMP-7 administration protects againstand -SMA confirmed the scoring results. In rats with
the tubulointerstitial fibrosis and renal destruction pro-sustained UUO for 10 days, administration of BMP-7
duced by UUO. The mechanism of action is partly re-reduced cellular infiltration. The administration of BMP-7,
lated to inhibition of renal tubular atrophy through theespecially the 300 g/kg bw dose, afforded greater pro-
prevention of tubular cell apoptosis and de-differentia-tection than did enalapril administration in the rats with
tion, which preserve tubular epithelial integrity as well as
UUO of 10 days duration.
epithelial cell phenotype, and to inhibition of interstitial
To assess the mechanism of protection by BMP-7 infiltration and interstitial fibroblast transformation. Sec-
against UUO-stimulated tubulointerstitial fibrosis, we ondary actions on preservation of renal blood also were
first examined the effects of UUO on tubular atrophy. contributory. Furthermore, BMP-7 administration at the
We quantitated tubular atrophy as described by Che- time of relief of obstruction was therapeutic and more
valier et al [49]. Unilateral ureteral obstruction for 5 potent than ACE inhibition. Our results clearly suggest
days with 5 days of recovery (with analysis at day 10) that BMP-7 is an important renal homeostatic factor that
significantly increased the number of atrophic tubules can suppress the impact of renal injury.
(Fig. 4B) over those in a sham-operated kidney (Fig. 4A).
The BMP-7 dose dependently decreased tubular atrophy
QUESTIONS AND ANSWERS(Fig. 4C). As in other studies [16], enalapril had no effect
on the tubular atrophy produced by UUO (Fig. 4D). Dr. John T. Harrington (Dean, Tufts University
School of Medicine, Boston, Massachusetts, USA): LetThese data demonstrate a significant difference between
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Fig. 4. BMP-7 blocks development of tubular atrophy following UUO. Coronal sections of kidneys stained with the periodic-acid Schiff stain to
highlight basement membranes. A. Sham-operated kidney. Basement membranes (BMs) are thin, BMs of different tubule segments often abut
each other, and no interstitial infiltrate is present. B. Vehicle-treated kidney. UUO for 5 days with release and analysis at day 10. Heavy interstitial
infiltrate and small atrophic tubules with thickened basement membranes. Some tubules have white blood cells in the lumens. C. 300 g/kg bw
of BMP-7 every other day. The pattern of basement membrane expression has basically been preserved as normal. D. Enalapril, 25 mg/kg daily.
The cellular infiltrate is less than that with vehicle treatment (B), but the tubular atrophy is essentially unchanged compared with the vehicle-
treated group.
me start by going back to your comments about ACE expect that in the setting of EB virus in the proximal
tubule, BMP-7 would be very effective.inhibitors and their ability to block fibroblast prolifera-
But is BMP-7 effective in organs other than the kidneytion. How does that work?
during chronic renal disease? As BMP-7 is a newly de-Dr. Hruska: That action appears to be indirect in
scribed hormone, an analogy to epoetin and calcitriol isthat fibroblast proliferation is a direct action of TGF-.
appropriate. These are both renal hormones with physio-Inhibition of TGF- transcription by ACE inhibition is
logic actions outside the kidney that are diminished dur-the means of inhibiting fibroblast proliferation.
ing chronic kidney disease. What are the extrarenal phys-Dr. Harrington: Does BMP-7 have a role in pre-
iologic actions of BMP-7? One of them is that it organizesventing fibrotic processes in other diseased organs, or is
and participates in osteoblast differentiation. Renal osteo-
the effect restricted to the kidney? dystrophy due to secondary hyperparathyroidism pro-
Dr. Hruska: A very interesting paper was published duces a pathologic skeletal state called osteitis fibrosa.
by Ed Nord’s group in the Journal of Clinical Investiga- The fibrosing cells in their bone marrow are osteoblast
tion demonstrating that primary interstitial nephritis is progenitors that cannot get into the differentiation pro-
associated with the development of the Epstein-Barr ge- grams because the marrow has been constricted. If you
nome in the proximal tubule [51]. There is no difference treat hyperparathyroidism, which is a high turnover bone
in terms of ACE inhibition between primary chronic disease, with BMP-7, you further increase bone forma-
interstitial nephritis versus secondary forms of interstitial tion rate, increase mineralization rates, and decrease bone
reabsorption. The most impressive thing is the disappear-nephritis, such as obstructive nephropathy, so we would
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ance of all of the fibroblastic cells and the bone marrow constitutive molecules of that cell. You might not see
tremendous regulation, and regulation might be an allfibrosis. Thus, at the level of the skeleton, there’s a marked
anti-fibrotic effect of BMP-7. At the level of the vascula- or none switch. Renal injury seems to eliminate BMP-7
expression. In the UUO model, the injury affects theture, there’s also an amazing effect that I think will be
important. collecting duct, where BMP-7 is made. Replacement of
BMP-7 protects against the injury. Is there a broaderDr. Ronald D. Perrone (Division of Nephrology,
New England Medical Center, Boston): Is it known pre- role for BMP-7 in chronic renal disease? The answer to
that is yes, and the basis for that answer is that specificcisely how the signaling pathway of BMP-7 functions?
Dr. Hruska: No, it is not. Perhaps the most intriguing BMP-7 receptors exist not only in the collecting duct,
but also in the proximal tubule and the glomerulus. Thepossibility is that BMP-7 could inhibit TGF-–induced
signaling. The BMPs and TGF- signal through tran- presence of the receptor in the proximal tubule defines
a paracrine role of BMP-7, but the presence of the recep-scription factors activated by their serine kinase recep-
tors. These transcription factors are called SMADs. There tor in the glomerulus according to renal development
suggests a hormonal role. The hormonal role that I wasare active SMADs, SMADs that form a dimer and transit
to the nucleus, and inhibitory SMADs. One possible mech- talking about for BMP-7 regulating osteoblast differenti-
ation would be further substantiated by protection ofanism by which a member of the superfamily inhibits
the signal transduction produced by another member of the glomerular compartment in chronic renal disease and
a differentiation function for BMP-7 probably in thethe family is that BMP-7 might stimulate an inhibitory
SMAD, thus decreasing TGF--stimulated active SMADs. glomerular compartment. Receptors for BMP-7 in com-
partments other than the collecting duct might indicateAnother possibility is that a primary inhibitory action of
BMP-7 signaling decreases expression of angiotensin II additional physiologic functions for BMP-7.
Dr. Madias: Angiotensin II activates transcription fac-and TGF-; that remains to be seen.
Dr. Perrone: Tubulointerstitial fibrosis is a substan- tor NF-B, which is central in the pathophysiologic cas-
cade of injury in tubulointerstitial disease. Do we knowtial component of the pathology of autosomal dominant
polycystic kidney disease. Is anything known about the mechanism by which such activation occurs? Also,
what is the effect of BMP-7 on NF-B activation?BMP-7 and cystic kidneys? Do we have any data on the
use of BMP-7 to alter cyst progression in animal models? Dr. Hruska: I don’t know the effect of BMP-7 on
NF-B activation. Those experiments are in progress.Dr. Hruska: We know that renal injury in general
decreases BMP-7 expression. We also know that BMP-7 The function of angiotensin II in activation of NF-B is
twofold. There is a direct effect and also an indirectexpression in the collecting duct decreases in renal cystic
diseases, but we have no idea what BMP-7 might do in effect that is most prominent through TGF-.
Dr. Andrew S. Levey (Chief, Division of Nephrol-polycystic kidney disease.
Dr. Andrew J. King (Division of Nephrology, New ogy, New England Medical Center): I think it’s particu-
larly interesting that you’ve shown the effect of BMP-7 inEngland Medical Center): Is there a difference between
enalapril and the AT-1 receptor blocker with respect to a model of interstitial disease for two reasons: interstitial
disease is a component of most kinds of chronic renaleffects following unilateral ureteral obstruction.
Dr. Hruska: There are two immediate possibilities disease, and also because the effects of ACE inhibitors
appear to be greater in patients with proteinuria, whichbut both appear not to be the case. The most likely pos-
sibility was that this difference was a kinin effect. The is most often associated with glomerular diseases rather
than interstitial diseases. For example, our work usingsecond possibility was that it was mediated through the
AT2 receptor. The data that I discussed showed that meta-analysis of controlled trials shows a benefit of re-
ducing proteinuria and blood pressure, and an additionalit wasn’t an AT2 receptor or a kinin effect [52]. One
possibility is that the difference is due to angiotensin benefit independent of those two. Hypertension and pro-
teinuria are more common in glomerular disease. Per-IV and the novel receptor. The angiotensin converting
enzyme would block that pathway, but the AT1 receptor haps the benefit of ACE inhibitors is independent of
lowering blood pressure and urinary protein, and occurswould not. All we know is that the two obvious explana-
tions were not the case. in the interstitium, as you have shown. What else needs
to be done before bringing drugs like BMP-7 or BMP-7Dr. Nicolaos E. Madias (Executive Academic Dean,
Tufts University School of Medicine): Are there known itself to clinical development?
Dr. Hruska: The next step on the basis of a seriesexamples of renal injury in which BMP-7 is spontane-
ously upregulated? of studies that have been completed but not reported
(although submitted as abstracts for the 2001 ASN/ISNDr. Hruska: None that I know of. I haven’t come
across anything that would indicate a stimulation of World Congress of Nephrology: Davies MR, et al; Lund
RJ et al; Wang S et al) is that BMP-7 is ready to goBMP-7 expression. In cells that are terminally differen-
tiated, the key differentiation factor is likely one of the from preclinical studies to human trials. While chronic
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tubulointerstitial disease is very significant, it might be Dr. Hruska: It has been difficult to bring therapeutic
agents effective in animal models of acute renal failuretoo limited of an indication, and BMP-7 might not be
developed solely for that indication. A broader context to the clinic. The models of acute renal failure are not
very reproducible from laboratory to laboratory. Second,of chronic renal disease in general would be a stronger
indication for which BMP-7 could be developed as a our models of acute renal failure do not correspond well
with human disease. Development of BMP-7 as a therapytherapy.
Dr. Harrington: Are there toxicity studies in hu- for acute renal failure was discontinued for these reasons.
Some studies demonstrated promising results.mans?
Dr. Hruska: No, only in animals. In the model of dia- Dr. Madias: Whereas controlled apoptosis might rep-
resent a mechanism of repair of renal injury, uncheckedbetic nephropathy, we used repeated tail vein injections
of BMP-7 for 16 weeks, 2 injections per week. We did apoptosis can have injurious consequences. You men-
tioned that BMP-7 decreased apoptosis in your experi-not see a single local sight reaction, nor was there any
vascular calcification, in 125 animals. We found no toxic- ments. Does this effect offer insights into the mechanism
of dysregulated apoptosis?ity. We performed a study related to heterotopic calcifi-
cation, which might be expected to be stimulated by Dr. Hruska: Probably, but I do not have any experi-
BMP-7, to directly look at this issue. Our hope was that mental data.
BMP-7 would not stimulate heterotopic calcification. Dr. Harrington: You showed a list of many proteins
The BMP-7 prevented vascular calcification in chronic whose expression are increased in unilateral ureteral ob-
renal disease, a state of severe vascular calcification. struction (Table 1). Yet we focus on BMP-7. What are the
Dr. King: Is BMP-7 detectable in urine? effects of these other overexpressed molecules as they
Dr. Hruska: Yes, it’s detectable in urine and in blood. dance along, and why is BMP-7 so effective?
You can measure changes in the urine with ELISAs, but Dr. Hruska: Most of those proteins listed in the table
the threshold of the detection limit for serum is such are involved in the destructive process downstream of
that you can’t measure any decrease. Thus, we don’t TGF- and NF-B. The hypothesis of BMP-7’s mecha-
have an ability to demonstrate that renal injury produces nism of action is that BMP-7 functions early in the de-
a decrease in blood levels, but it does decrease urinary structive pathway and that the proteins that are upregu-
BMP-7 excretion. You can ask, why is BMP-7 excreted lated will be inhibited by BMP-7.
in the urine? Perhaps urinary BMP-7 has a differentia-
Reprint requests to Dr. K. Hruska, Department of Pediatrics, Campustion role in the urinary tract and the bladder.
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